Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Lisa Cordes
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute | Journal of Clinical Oncology
Dai Chihara, MD, PhD1,2; Erich P. Huang, PhD3; Shanda R. Finnigan, MPH, RN4; Lisa M. Cordes, PharmD5; Nebojsa Skorupan, MD2; Yoko Fukuda, MD4; Larry V. Rubinstein, PhD3; S. Percy Ivy, MD4; James H. Doroshow, MD4; Loretta J. Nastoupil, MD1; Christopher R.
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute | Journal of Clinical Oncology
Abstract Cancer drug development has largely shifted from cytotoxic chemotherapy to targeted treatment in the past two decades. Although previous studies have highlighted improvement in response rates in recent phase I trials, disease-focused reporting is limited.
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute | Journal of Clinical Oncology
Article Tools ORIGINAL REPORTS Hematologic Malignancy Abstract Full Text PDF Figures and Tables Supplements Abstract Cancer drug development has largely shifted from cytotoxic chemotherapy to targeted treatment in the past two decades. Although previous studies have highlighted improvement in response rates in recent phase I trials, disease-focused reporting is limited.
Management of Adverse Events Associated with Cabozantinib Plus Nivolumab in Renal Cell Carcinoma: A Review
Choueiri T.K. Halabi S. Sanford B.L. Hahn O. Michaelson M.D. Walsh M.K. et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol. 2017; 35: 591-597 Choueiri T.K. Escudier B. Powles T. Mainwaring P.N. Rini B.I. Donskov F. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015; 373: 1814-1823 Motzer R.J. Escudier B.
The Dietary Supplement Health And Education Act: are we healthier and better informed after 27 years?
Tristan M Sissung Lisa M Cordes William D Figg Published:July, 2021DOI:https://doi.org/10.1016/S1470-2045(21)00084-X In the early 1990s, the US Food and Drug Administration (FDA) was considering imposing stricter standards on vitamins, minerals, and other food additives that could cause adverse effects. This action followed several raids on sellers of potentially dangerous or unproven dietary and herbal products.
Endocrine‐Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management
Abstract Immune checkpoint inhibitors have proven to be effective for various advanced neoplasia. Immune‐related adverse events (irAEs) as a result of increased T cell activation are unique and potentially life‐threating toxicities associated with the use of immune checkpoint inhibitors.
An outsider artist's unblinking look at racial terror
Arts & Culture APT Alabama Warning: This story contains disturbing imagery. BIRMINGHAM, Ala. — Mary Frances Whitfield spent her youth in Birmingham, Alabama, with a strong-willed and brave grandmother who was on the forefront of the civil rights movement. Her grandmother marched across the Edmund-Pettus Bridge from Selma to Montgomery, alongside Martin Luther King Jr. and hundreds of other protesters. She even lost her job because of her involvement in the movement.
How growing up in rural Alabama shaped this author and dancer
Arts & Culture APT Alabama TRIANA, Ala. — On a hot spring day, Brontez Purnell fans himself inside his childhood church, a place where he first started performing as a child in the choir, and that has shaped so much of who he is as a person and an artist. In his youth, the church in Triana, Alabama, didn’t have a microphone, so the solos went to whoever could project their voice the loudest. That lesson of projection has stayed with him throughout his life.
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
Between Jan 31, 2013, and Oct 8, 2014, 53 patients were enrolled (four patients at 1 mg/kg, 13 at 3 mg/kg, 15 at 10 mg/kg, and 21 at 20 mg/kg). 18 patients were analysed in the dose-limiting toxicity analysis set: three at dose level 1 (1 mg/kg), three at dose level 2 (3 mg/kg), six at dose level 3 (10 mg/kg), and six at dose level 4 (20 mg/kg). Only one dose-limiting toxicity occurred, at the 20 mg/kg dose, and thus the maximum tolerated dose was not reached.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Lisa
Contact Lisa, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack